Notably, Meg3 deficiency dramatically attenuated tumor growth in ApcminmiR-708−/− mice, hinting that the combined application of agomirs of Meg3 and antagomirs of miR-708 might contribute to therapy of CRC in the clinic. This evidence concerns the gene MEG3 and colorectal carcinoma.